Skip to main content
Journal cover image

Targeting YAP-mediated HSC death susceptibility and senescence for treatment of liver fibrosis.

Publication ,  Conference
Du, K; Maeso-Díaz, R; Oh, SH; Wang, E; Chen, T; Pan, C; Xiang, K; Dutta, RK; Wang, X-F; Chi, J-T; Diehl, AM
Published in: Hepatology
June 1, 2023

BACKGROUND AND AIMS: Liver fibrosis results from the accumulation of myofibroblasts (MFs) derived from quiescent HSCs, and yes-associated protein (YAP) controls this state transition. Although fibrosis is also influenced by HSC death and senescence, whether YAP regulates these processes and whether this could be leveraged to treat liver fibrosis are unknown. APPROACH AND RESULTS: YAP activity was manipulated in MF-HSCs to determine how YAP impacts susceptibility to pro-apoptotic senolytic agents or ferroptosis. Effects of senescence on YAP activity and susceptibility to apoptosis versus ferroptosis were also examined. CCl 4 -treated mice were treated with a ferroptosis inducer or pro-apoptotic senolytic to determine the effects on liver fibrosis. YAP was conditionally disrupted in MFs to determine how YAP activity in MF-HSC affects liver fibrosis in mouse models. Silencing YAP in cultured MF-HSCs induced HSC senescence and vulnerability to senolytics, and promoted ferroptosis resistance. Conversely, inducing HSC senescence suppressed YAP activity, increased sensitivity to senolytics, and decreased sensitivity to ferroptosis. Single-cell analysis of HSCs from fibrotic livers revealed heterogeneous sensitivity to ferroptosis, apoptosis, and senescence. In mice with chronic liver injury, neither the ferroptosis inducer nor senolytic improved fibrosis. However, selectively depleting YAP in MF-HSCs induced senescence and decreased liver injury and fibrosis. CONCLUSION: YAP determines whether MF-HSCs remain activated or become senescent. By regulating this state transition, Yap controls both HSC fibrogenic activity and susceptibility to distinct mechanisms for cell death. MF-HSC-specific YAP depletion induces senescence and protects injured livers from fibrosis. Clarifying determinants of HSC YAP activity may facilitate the development of novel anti-fibrotic therapies.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Hepatology

DOI

EISSN

1527-3350

Publication Date

June 1, 2023

Volume

77

Issue

6

Start / End Page

1998 / 2015

Location

United States

Related Subject Headings

  • Senotherapeutics
  • Mice
  • Liver Cirrhosis
  • Liver
  • Hepatic Stellate Cells
  • Gastroenterology & Hepatology
  • Cell Death
  • Animals
  • Adaptor Proteins, Signal Transducing
  • 3204 Immunology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Du, K., Maeso-Díaz, R., Oh, S. H., Wang, E., Chen, T., Pan, C., … Diehl, A. M. (2023). Targeting YAP-mediated HSC death susceptibility and senescence for treatment of liver fibrosis. In Hepatology (Vol. 77, pp. 1998–2015). United States. https://doi.org/10.1097/HEP.0000000000000326
Du, Kuo, Raquel Maeso-Díaz, Seh Hoon Oh, Ergang Wang, Tianyi Chen, Christopher Pan, Kun Xiang, et al. “Targeting YAP-mediated HSC death susceptibility and senescence for treatment of liver fibrosis.” In Hepatology, 77:1998–2015, 2023. https://doi.org/10.1097/HEP.0000000000000326.
Du K, Maeso-Díaz R, Oh SH, Wang E, Chen T, Pan C, et al. Targeting YAP-mediated HSC death susceptibility and senescence for treatment of liver fibrosis. In: Hepatology. 2023. p. 1998–2015.
Du, Kuo, et al. “Targeting YAP-mediated HSC death susceptibility and senescence for treatment of liver fibrosis.Hepatology, vol. 77, no. 6, 2023, pp. 1998–2015. Pubmed, doi:10.1097/HEP.0000000000000326.
Du K, Maeso-Díaz R, Oh SH, Wang E, Chen T, Pan C, Xiang K, Dutta RK, Wang X-F, Chi J-T, Diehl AM. Targeting YAP-mediated HSC death susceptibility and senescence for treatment of liver fibrosis. Hepatology. 2023. p. 1998–2015.
Journal cover image

Published In

Hepatology

DOI

EISSN

1527-3350

Publication Date

June 1, 2023

Volume

77

Issue

6

Start / End Page

1998 / 2015

Location

United States

Related Subject Headings

  • Senotherapeutics
  • Mice
  • Liver Cirrhosis
  • Liver
  • Hepatic Stellate Cells
  • Gastroenterology & Hepatology
  • Cell Death
  • Animals
  • Adaptor Proteins, Signal Transducing
  • 3204 Immunology